Stereotactic Radiation Therapy for Metastatic Kidney Cancer Being Treated With Sunitinib

Official Title

A Phase II, Multi-Centre Study, of Stereotactic Radiation Therapy for Oligo-Progression in Metastatic Renal Cell Cancer Patients Receiving 1st Line Sunitinib Therapy


Stereotactic radiation therapy (SRT) is a newer type of focused radiation therapy that precisely and accurately delivers high dose radiation to a tumour, while sparing much of the nearby normal organs. The use of stereotactic radiation therapy results in high rates of tumour destruction with minimal side effects which are very well tolerated. Often stereotactic radiation therapy has been used to try to cure patients who have an early stage cancer which has not spread, but there is less experience with using it in patients with cancer which has spread. The purpose of this study is to measure how well stereotactic radiation therapy can destroy kidney cancer tumours which are no longer being controlled by Sunitinib and to measure how much longer such an approach will allow patients to stay on Sunitinib before needing to switch to another medication. Stereotactic radiation therapy will be used to treat only the growing tumours and then patients will continue with Sunitinib.

Trial Description

Primary Outcome:

  • To evaluate local control at one year of metastases treated with stereotactic radiation therapy in patients who present with oligo-progression while receiving first-line treatment with Sunitinib.
Secondary Outcome:
  • To evaluate progression free survival after stereotactic radiation therapy while continuing to receive first-line systemic therapy with Sunitinib.
  • To evaluate the acute and late toxicity to stereotactic radiation therapy.

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society